BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary light-chain (AL) amyloidosis.
- You are 18 years or older.
- You have measurable disease, meaning certain protein levels in your blood are high enough.
- You are in reasonably good health (ECOG performance status 0-2).
- Your organs (kidneys, liver, bone marrow) function well enough per lab tests.
- You agree to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new drugs, sonrotoclax and a BCMA bispecific antibody, for people newly diagnosed with AL amyloidosis. The treatment aims to target and destroy the abnormal cells that cause the disease, potentially improving outcomes.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
Hear when a new Systemic Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.